NSAID-induced nephropathies


Cite item

Full Text

Abstract

Risk factors, pathogenesis and approaches to treatment and prevention of NSAID-induced nephropathies are discussed.

About the authors

- -

References

  1. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18-24.
  2. Tamblin R., Berkson L., Dauphinee D. еt al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med. 1997; 127: 429-438.
  3. Steinmeyer J. Pharmacological basis for the therapy of pain and inflam-mation with nonsteroidal anti-inflammatory drugs. Arthritis Res. 2000; 2: 379-385.
  4. Abramson S., Weaver A. Current state of therapy for pain and inflammation. Arthritis Research&Therapy. 2005; 7(suppl.4):1-6.
  5. Juni P., Rutjes A.W.S., Dieppe P.A. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? Adequate analysis of the CLASS trial indicates that this may not be the case. BMJ. 2002; 324: 1287-1288.
  6. Sandler R.S., Halabi S., Baron J.A. et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. NEJM. 2003;348:883-890.
  7. Zhang Y., Coogan P.F., Palmer J.R. et al. Use of nonsteroidal anti-inflammatory drugs and risk of breast cancer : the case-control surveillance study revisited. Am J Epidemiol. 2005;162:165-170.
  8. Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128-131.
  9. Moriland L. et. al. Management of rheumatoid arthritis: the historical context. J Rheumatol. 2001; 286( 6): 1431-1452.
  10. Lewis S.C., Langman M.J., Laporte J.R. et al. Dose-response relationship between individual nonaspirinnonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient date. Br J Clin Pharmacol. 2002; 54: 320-326.
  11. Pedersen A.K., Fitzgerald G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase, NEJM. 1984,311:1206-1211.
  12. Vane J.R. Inhibition of prostaglandin synthesis as the mechanism of action for aspirin-like drugs. Nature New Biol. 1971; 231: 232-235.
  13. Masferrer J.L. et al. Selective regulation of cellular cyclooxygenase by dexametason and endotoxin in mice. J Clin Invest. 1990; 86: 1375-1379.
  14. Davies N.M., Good R.L., Roupe K.A., Yanes J.A. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? - not as easy as 1,2,3. J Pharm Pharmaceut Sci. 2004; 7(2): 217-226.
  15. Nasrallah R., Hebert R.L. Prostacyclin signaling in the kidney: implications for health and disease. Am J Physiol Renal Physiol. 2005; 289:235-246.
  16. Satoh T., Ishikava Y., Kataoka Y. et al. CNS-specific prostacyclin ligands as neuronal survival-promoting factors in the brain. Eur J Neurosc. 1999; 11: 3115-3124.
  17. Cheng Y., Austin S.C., Rocca B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296: 539-541.
  18. McLaughlin VV, Genthner DE, Panella M.М. et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. NЕJM. 1998; 338: 273-277.
  19. Vachiery J.L., Naeije R. Treprostinil: stable long acting prostacyclin analog used for treatment pulmonary arteriolar hypertension. Expert Rev Cardiovasc Ther. 2004; 2: 183-191.
  20. Egan K.M., Lawson J.A., Fries S. et al. COX-2 derived prostacycline confers atheroprotection on female mice. Science. 2004;306:1954-1957.
  21. Komhoff M., Grone H.J., Klein T. et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function, Am J Physiol. 1997; 272: 460-468.
  22. Qi Z., Cai H., Morrow J.D., Brayer M.D. Differentiation of cyclooxygenase 1 and 2-derived prostanoids in mouse kidney and aorta, Hypertension. 2006;48:323-328.
  23. Khan K.N.M., Paulson S.K., Verburg K.M. et al. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int. 2002; 61:1210-1219.
  24. Feeman R.H., Davis J.O., Villarreal D. Role of renal prostaglandins in the control of renin release. Circ Res. 1984; 54: 1-9.
  25. Farman N., Pradelles P., Bonvalet J.P., PGE2, 6-keto-PGF1α and TXB2 synthesis along the rabbit nephron. Am J Physiol Renal Рhysiol. 1987; 252: 53-59.
  26. Schliebe N., Strotmann R., Busse K. et al. V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasis, Am J Physiol Renal Рhysiol. 2008; 295: 1177-1190.
  27. Clive D.M., Stoff J.S. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. NEJM. 1984; 310:563-572.
  28. Edwards R.M. Effects of prostaglandins on vasoconstrictor action in isolated renal arterioles. Am J Physiol. 1985; 248:779-789.
  29. Bonventre J.V., Nemenoff R. Renal tubular arachidonic acid metabolism. Kidney Int. 1991; 39: 438-449.
  30. Schlondorff D. Renal prostaglandin synthesis: sites of production and specific actions of prostaglandins. Am J Med. 1986; 81 (2B): 1-11.
  31. Morrison A.R., Biochemistry and pharmacology of renal arachidonic acid metabolism. Am J Med. 1986; 80 (suppl.1A): 3-11.
  32. Pelavo J.C. Renal adrenergic effector mechanism: glomerular sites for prostaglandin interaction. Am J Physiol. 1988; 254 (23): 184-190.
  33. Abdel-Kader Kh., Palevsky P. Acute kidney injury in the elderly. Clin Geriatr Med. 2009;25( 3): 331-358.
  34. Lydford S., McKechnie K., Dougall I. Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br J Pharmacol. 1996; 117: 13-20.
  35. Reeves W.B., Foley R.J., Weinman E.J. Nephrotoxicity from nonsteroidal anti-inflammatory drugs. South Med J. 1985; 78 (3):318-322.
  36. Rodrigues F., Llinas M.T., Gonzales J.D. et al. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension . 2000; 36: 276-281.
  37. Rossat R.J., Maillard M., Nussberger J. et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999; 66: 76-84.
  38. Swan S.K., Rudy D.W., Lasserter K.C. et al. Effect of cyclooxygenase-2 inhib ition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med. 2000; 133: 1-9.
  39. Cheng H.F., Harris R.C. Cyclooxigenases, the kidney and hypertension. Hypertension. 2004; 43: 525-530.
  40. Harris R.C. Cyclooxygenase-2 inhibition and renal physiology, Am J Cardiol. 2002; 89: 10-17.
  41. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specific inhibitors. Am J Med. 2001; 110: 33-42.
  42. Zhang J., Ding E., Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events. Meta-analysis of randomized trials. JAMA. 2006; 296 (1)3: 1619-1632.
  43. Singh G. Recent consideration in nonsteroidal anti-inflammatory drugs gastropathy. Am J Med. 1998; 105: 31-38.
  44. Sandhu G.K., Heyneman C.A. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother. 2004;38:700-704.
  45. Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal anti-inflammatory drugs. Evidence of a common mechanism. Br J Clin Pharmacol. 1999; 47(2):203-210.
  46. Schlondorff D. Renal complication of nonsteroidal anti-inflammatory drugs, Kidney International. 1993; 44: 643-653.
  47. Singh A.K., Colvin R.B. Case 36-2003: a 68 year old women with impaired renal function, NEJM. 2003;349: 2055-2063.
  48. Murray M.D., Brater D.C. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol. 1993; 33: 435-465.
  49. Schlondorff D. Renal complications of non-steroidal anti-inflammatory drugs (NSAID). Nephrol Dial Transplant. 1996; 11(9):1907-1911.
  50. Griffin M.R., Yared A., WayneA.R. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000;151:488-496.
  51. Kohlhagen J., Katrib A., Stafford L. et al. Does regular use of non-steroidal anti-inflammatory drugs increase the risk of renal disease? Nephrology. 2002; 7(1):5-11.
  52. Winkelmayer W.C., Waikar S.S., Mogun H., Solomon D.H. Nonselective and cyclooxygenase-2 selective NSAID and acute kidney injury. Am J Med. 2008; 121( 12): 1092-109.
  53. Schneider V., Levesque L.E., Zhang B. et al. Association of selective and conventional nonsteroidal anti-inflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006; 164(9):881-889.
  54. Graham M.G. Acute renal failure to high-dose celecoxib. Ann Intern Med. 2001;135: 69-70.
  55. Alper A.B., Meleg-Smith S., Krane N.K. Nephrotic syndrome and interstitial nephriris associated with celecoxib. Am J Kidney Dis. 2002; 40: 1086-1090.
  56. Tabibian J.H., Tabibian N., Kaufman D.M. Late-onset celecoxib-induced combine hepato-nephrotoxicity. Br J Clin Pharmacol. 2008; 66(1):150-151.
  57. Abraham P.A., Keane W.F. Glomerular and interstitial disease induced by non-steroidal anti-inflammatory drugs. Am J Nephrol. 1984; 4: 1-6.
  58. Radford M.G., Holley K.E., Grande J.P. et al. Reversible membranous nephropathy associated with the use anti-inflammatory drugs. JAMA. 1996; 276: 466-469.
  59. Porile J.L., Bakris G.L., Garella S.A. Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. J Clin Pharmacol. 1990; 30:468-475.
  60. O'Callaghan C.A., Andrews P.A., Ogg C.G. Renal disease and use of topical non-steroidal anti-inflammatory drugs. BMJ. 1994;308:110-111.
  61. Fellner S.K. Piroxicam induced acute interstitial nephritis and minimal change nephritic syndrome. Am J Nephrol. 1985;5:142-143.
  62. Kleinknecht D., Landais P., Goldfarb B. Analgesis and nonsteroidal anti-inflammatory drug-associated acute renal failure: a prospective collaborative study. Clin Nephrol. 1986; 25: 275-281.
  63. Huerta C., Castellsague J., Varas-Lorenzo C., Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005; 45: 531-539.
  64. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001; 60: 804-817.
  65. Sandler D.P., Burr R., Weinberg C.R. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med. 1991; 115: 165-172.
  66. Buysen J. G. M., Houthoff H. J., Krediet R. T., Arisz L. Acute Interstitial Nephritis: A Clinical and Morphological Study in 27 Patients. Nephrol Dial Transplant. 1990; 5: 94-99.
  67. Schilliger F., Montagnac R., Milcent T. Membranous glomerolonephritis after diclofenac treatment. Kidney Int. 1987; 32: 428-429.
  68. Kim M.J., Heim M., Mayer M. Effect of corticosteroids during ongoing drug exposure in pantoprazole-induced interstitial nephritis. Nephrol Dial Transpl. 2010; 25( 5): 1716-1719.
  69. Szalat A., Krasilnikov I., Bloch A. et al Acute renal failure and interstitial nephritis in a patient treated with rofecoxib: case report and review of the literature. Arthritis&Rheumatism. 2004; 51(4):670-673.
  70. Whelton A., Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundation and clinical implications. Am J Med. 1999;106: 13-24.
  71. Gertz B.J., Krupa J.A., Sperling R.S., Reicin A. A comparison of adverse renovascular experience among osteoarthritis patients with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr Med Res Opin. 2002; 18: 82-91.
  72. Osterhaus J.T., Burke T.A., May C. et al Physician-reported management of oedema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. Clin Ther. 2002; 24: 969-989.
  73. CollantesE., Curtis S.P., Wing Lee K. A multinational randomized controlled clinical trial of etoricoxib in the treatment of rheumatoid arthritix. BMC Family Prac. 2002;( 3) 1-10.
  74. Chang I., Harris R.C. Are all COX-2 inhibitors created equal? Hypertension. 2005;45:178-180.
  75. Мухин Н.А. Избранные лекции по внутренним болезням. М.:»Литера» 2006;с.111.
  76. Gurwitz J.H., Everit D.E., Monane M. et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol. 1996; 51: 74-79.
  77. Polonia J., Boaventura I., Gama G. et al. Influence of non-steroidal anti-inflammatory drugs on renal funciton and 24 h ambulatory blood pressure-reducing effect of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens. 1995; 13: 925-931.
  78. Sheridan R., Montgomery A.A., Fahey T. NSAID use and BP in treated hypertensives: a retrospective controlled observational study. J Human Hypertension. 2005; 19: 445-450.
  79. Miyataka M., Rich K.A., Yamamoto T., Bing R.G. Nitric oxide, anti-inflammatory drugs on renal prostaglandins and cyclooxygenase-2. Hypertension. 2002; 39: 785-789.
  80. Schnitzer Th.J., Hochberg M.C., Marrero Ch.E. et al. Efficacy and Safety of naproxcinod in patients with osteoarthritis of the knee: a 53- week prospective randomized multicenter study. Seminar in Arthritis and Rheumatism. 2011; 40(4):285-297.
  81. Nasser S.M., Patel M., Bell G.S., Lee T.H. The effect of aspirin desensitiza-tion on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med. 1995; 151: 1326-1330.
  82. Nickerson-Nutter C.L., Medvedeff E.D. The effects of leucotriene synthesis inhibition in models of acute and chronic inflammation. Arthritis& Rheuma-tism. 1996; 39: 512-521.
  83. Gambaro G., Perazella M.A. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med. 2003; 253(6): 643-652.
  84. Whelton A. Nephrotoxicity of non-steroidal anti-inflammatory drugs: physiologic foundation and clinical implication. Am J Med. 1999; 106: 13-24.
  85. Celotti F., Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res. 2001; 43: 429-436.
  86. Algate D.R. et al General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pirrolizine-5-yl]-acetic acid in experimental animals. Arzneimittel-Forsching. 1995; 45: 159-165.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies